ClinicalTrials.Veeva

Menu

Differentiation Induction in Acute Myelogenous Leukemia

U

University of Bergen

Status and phase

Completed
Phase 2
Phase 1

Conditions

Acute Myelogenous Leukemia

Treatments

Drug: Valproic acid
Drug: Theophyllin
Drug: all-trans retinoic acid (ATRA)

Study type

Interventional

Funder types

Other

Identifiers

NCT00175812
REK-Vestnr21503

Details and patient eligibility

About

Hypothesis: Differentiation induction therapy in acute myelogenous leukemia (AML) can be used to achieve disease control and stabilize peripheral blood counts in patients with acute myelogenous leukemia.

Adult patients (<18 years of age) who can be included: Elderly patients (>60 years of age) with newly diagnosed AML who cannot achieve standard chemotherapy, patients with relapsed or resistant AML. Patients with relapsed or resistant AML who cannot receive intensive chemotherapy.

Treatment: Patients will be treated with all-trans retinoic acid (oral administration), valproic acid (7 days intravenous administration and later oral administration)and theophyllamine (7 days intravenous administration and later oral administration). Duration of treatment at least 2 months or until disease progression. Maximal duration of treatment 2 years.

Followup: Clinical evaluation, peripheral blood samples, bone marrow samples.

Full description

Patients to be included:

  1. Elderly patients above 60 years of age with newly diagnosed acute myelogenous leukemia (AML) who cannot receive conventional intensive chemotherapy.
  2. Adult patients of any age (> 18 years of age)with relapsed or resistant AML who cannot receive conventional intensive chemotherapy or allogeneic stem cell transplantation.

We plan to include at least 20 patients, but if possible 30 patients during a 3 years period. The first patient was included November 2004.

Treatment:

All-trans retinoic acid (ATRA) administered orally 22.5 mg/m2 twice daily for 14 days, repeated every third month.

Valproic acid started on day 3 of ATRA therapy, the first week as intravenous administration and later oral administration.

Theophyllamine started on day 3 of ATRA therapy, the first week as intravenous administration and later oral administration.

Duration of treatment at least 2 months unless side effects,until disease progression or an overall duration of treatment of 2 years.

Supportive therapy according to the hospitals general guidelines.

Followup:

The first week treatment in hospital. Later out-patient treatment with regular controls including clinical examination, peripheral blood parameters (including serum valproic acid and theophyllamin levels), bone marrow samples.

Enrollment

24 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Recently diagnosed acute myelogenous leukemia (AML)
  • Patients above 60 years of age
  • Patients who cannot receive conventional chemotherapy
  • Patients with relapsed or refractory AML independent of age

Exclusion criteria

  • Chronic myelogenous leukemia in blast phase
  • Intolerance to the study drugs
  • Serious liver disease
  • No informed consent

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

24 participants in 1 patient group

ATRA plus valproic acid plus theophyllin
Experimental group
Description:
ATRA for 14 days, continuous treatment with valproic acid and theophyllin
Treatment:
Drug: Theophyllin
Drug: all-trans retinoic acid (ATRA)
Drug: Valproic acid

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems